Nearly three out of four patients on subcutaneous VK2735 moved down at least one BMI category in just 13 weeks, according to a new exploratory analysis of Viking Therapeutics’ Phase 2 VENTURE trial presented at ObesityWeek 2026 in Washington, D.C. Only 15% of placebo recipients did the same. That gap matters because BMI category improvement, not just percentage weight loss, tracks more directly with cardiovascular and metabolic risk reduction, and the cardiometabolic data from VENTURE support that link.
Among participants who improved by at least one BMI category, systolic blood pressure dropped 9 mmHg on average, triglycerides fell by about 20 mg/dL, and LDL cholesterol declined 12.3 mg/dL. Patients whose BMI category did not change still saw some improvement, but the reductions were roughly half as large across those same markers. Notably, none of the VK2735-treated participants experienced an increase in BMI category, compared with 12% of placebo participants in the Class I group who actually moved up to Class II. The Class II subgroup showed a marked shift: 80% of VK2735-treated patients in that group transitioned to Class I obesity, with an additional 2% reaching the Overweight category, against 20% on placebo transitioning to Class I.
The VENTURE efficacy numbers arriving in this context carry weight because Zepbound (tirzepatide) and Wegovy (semaglutide) have set a high practical bar in the market, and VK2735’s previously reported top-line weight loss of up to 14.7% at 13 weeks competes on efficacy terms. The cardiometabolic secondary data now give Viking a sharper clinical argument: weight loss from VK2735 appears to translate into measurable metabolic improvements within a quarter, not just a number on a scale.
The second ObesityWeek poster covered baseline characteristics from the ongoing Phase 3 VANQUISH-2 trial, which is enrolling adults with overweight or obesity plus type 2 diabetes, the demographic where cardiometabolic benefit claims will face the most scrutiny from payers and regulators. VANQUISH-2 runs 78 weeks with percent change in body weight as the primary endpoint. Whether the cardiometabolic signals seen at 13 weeks in VENTURE hold and deepen at that longer duration is the number Viking’s Phase 3 program now has to deliver.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.

